Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer

Enzalutamide is the first second-generation nonsteroidal androgen receptor (AR) antagonist with a strong binding affinity to AR. Most significantly, enzalutamide can prolong not only overall survival time and metastatic free survival time for patients with lethal castration-resistant prostate cancer...

Full description

Bibliographic Details
Main Authors: Pravien Rajaram, Alyssa Rivera, Kevin Muthima, Nicholas Olveda, Hubert Muchalski, Qiao-Hong Chen
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Molecules
Subjects:
androgen receptor
prostate cancer
enzalutamide
apalutamide
darolutamide
Online Access:https://www.mdpi.com/1420-3049/25/10/2448

Internet

https://www.mdpi.com/1420-3049/25/10/2448

Similar Items